CALL - SPRINTER OPEN END - AMGEN | Delayed Deutsche Boerse AG 04:32:09 2024-06-14 am EDT | ||
| 8.53 EUR | -0.93% |
|
| Current month | -5.59% | ||
| 1 month | -8.31% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 8.53 | -0.93% |
| 24-06-13 | 8.61 | -1.82% |
| 24-06-12 | 8.77 | -0.79% |
| 24-06-11 | 8.84 | -2.43% |
| 24-06-10 | 9.06 | -2.58% |
Delayed Quote Deutsche Boerse AG
Last update June 14, 2024 at 04:32 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VV16X4 |
| ISIN | DE000VV16X45 |
| Date issued | 2022-05-06 |
| Strike | 207.2 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.48 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.49 € |
|---|---|
| Lowest since issue | 1.86 € |
| Spread | 0.12 € |
| Spread % | 1.39% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
298.5
USD
Average target price
316.3
USD
Spread / Average Target
+5.95%
- Stock Market
- Certificates
- Certificat
